ISET 2025 - 1-Year results from the RESOLV I trial show positive clinical outcomes and a low restenosis rate.

Dr Marianne Brodmann (Medical University of Graz, AT) joins us onsite at ISET 2025 to discuss the findings from RESOLV I (NCT04912323). The RESOLV I trial is the first-in-human study to determine the safety and efficacy of the MAGNITUDE bioresorbable drug-eluting scaffold (R3 Vascular Inc.) in patients with severe peripheral arterial disease that has reduced the blood supply to their leg. The primary outcome measures were the composite endpoint of freedom from major adverse limb event and primary patency of the target lesions.

Clinical outcomes were positive, with a low rate of restenosis.

Interview Questions:

1. What is the importance behind the RESOLV I trial?
2. Could you tell us about the unique features of the MAGNITUDE scaffold?
3. What was the study design and patient population?
4. What are the key findings?
5. What are your take-home messages?
6. What further research is needed?

Recorded remotely from Austria, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.